论文部分内容阅读
目的对比辛伐他汀与降脂灵对高脂血症患者超敏c反应蛋白(hs-CRP)水平的影响。方法56例高脂血症患者随机分为两组:辛伐他汀组采用辛伐他汀20mg?d,降脂灵组采用降脂灵5片/次,3次/d,与治疗前及治疗后4周分别测定hs-CRP水平、血脂、肝功能、肌酶等指标。结果辛伐他汀组治疗4周后血脂、hs-CRP较治疗前明显下降,差异有统计学意义(P<0.05),降脂灵组上述指标较治疗前虽有下降,但差异无统计学意义;两组治疗前后肝功能及肌酶无明显变化。结论辛伐他汀显著降低高脂血症患者血脂及hs-CRP水平,具有防治动脉粥样硬化的作用,且临床应用安全。
Objective To compare the effects of Simvastatin and Jiangzhi Ling on the levels of hs-CRP in patients with hyperlipidemia. Methods Sixty-six patients with hyperlipidemia were randomly divided into two groups: simvastatin 20 mg? D for simvastatin group, 5 tablets for lipid lowering and / or 3 times / 4 weeks were measured hs-CRP levels, lipids, liver function, muscle enzymes and other indicators. Results The blood lipid and hs-CRP in simvastatin group were significantly lower than those before treatment (P <0.05), but the difference was not statistically significant The liver function and muscle enzymes had no significant changes before and after treatment in both groups. Conclusion Simvastatin can significantly reduce the level of serum lipids and hs-CRP in patients with hyperlipidemia, which has the effect of prevention and treatment of atherosclerosis and is safe in clinical application.